Indenone Derivative Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis, such as bisphosphonates and hormonal drugs, suffer from low absorption rates, side effects, and increased risks of cancer, while existing therapies often target mature osteoclasts rather than reducing their formation, and there is a need for more effective and safer long-term solutions.
Innovation Solution
Development of a novel indenone derivative that increases osteoblastic activity and inhibits osteoclastic bone resorption, formulated into a pharmaceutical composition for preventing or treating osteoporosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonates are used to treat osteoporosis, then bone resorption is inhibited, but absorption rate is low (10% or less) and side effects occur
Solution Approach 1:
The patent applies parameter changes by developing a novel chemical compound (indenone derivative) with modified molecular structure and properties. The compound features a specific chemical formula with variable substituents (R1, R2, R3, X, Y, n) that can be adjusted to optimize both absorption characteristics and osteoclast inhibition activity, thereby improving the therapeutic index compared to existing bisphosphonates
Solution Approach 2:
The patent creates a new compound that copies and improves upon the mechanism of action of existing osteoporosis treatments. The indenone derivative replicates the bone-resorption inhibitory effect of bisphosphonates and estrogen while attempting to eliminate their side effects and low bioavailability through structural optimization
2Reliability
If hormonal drugs are used for long-term treatment, then bone mass is maintained, but risk of cancer increases
Solution Approach 1:
The patent extracts and isolates the beneficial effect of hormonal therapy (osteoclast inhibition and bone mass maintenance) while removing the harmful hormonal components that cause cancer risk. The indenone derivative achieves bone protection through a non-hormonal mechanism, specifically by inhibiting osteoclast formation and activity without the systemic hormonal effects that lead to malignancy
Solution Approach 2:
The patent converts the harmful long-term hormonal exposure into a beneficial localized effect on osteoclasts. By targeting the specific cellular mechanism of osteoclastogenesis and osteoclast activity with a non-hormonal compound, the treatment achieves bone protection without the carcinogenic side effects of prolonged hormonal therapy
3Reliability
If current therapies target mature osteoclasts, then bone resorption is reduced, but formation of new osteoclasts is not prevented
Solution Approach 1:
The patent applies preliminary action by targeting the formation and differentiation of osteoclasts at an earlier stage rather than only affecting mature osteoclasts. The indenone derivative interferes with the osteoclastogenic process itself, preventing the formation of new bone-resorbing cells before they become fully functional, thereby providing more sustained long-term efficacy
Data Source
AI summary
An indenone derivative of formula (1) is effective in enhancing the activity of osteoblastic cells and inhibiting bone resorption by osteoclastic cells, and a pharmaceutical composition comprising the indenone derivative or a pharmaceutically acceptable salt thereof is useful for preventing or treating bone diseases such as osteoporosis.